Report excerpt eXoZymes’ recent Q3 investor call was, in my view, a genuine inflection point for the company. For the first time, management laid out a clear, commercially driven roadmap that connects near-term revenues, potential multi-billion-dollar exits and a disciplined capital and operating strategy designed to protect and compound shareholder value.
